Last reviewed · How we verify
Comparator: glimepiride
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Comparator: glimepiride |
|---|---|
| Also known as | Amaryl® |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Sulfonylurea |
| Target | Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose in patients with type 2 diabetes by increasing endogenous insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Dizziness
- Headache
- Nausea
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes (NA)
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) (PHASE4)
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) (PHASE4)
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes (NA)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: glimepiride CI brief — competitive landscape report
- Comparator: glimepiride updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI